NCT00321464View on ClinicalTrials.gov

A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.

PHASE3CompletedINTERVENTIONAL

Enrollment

2,049

Participants

Timeline

Start Date

April 1, 2006

Primary Completion Date

July 20, 2009

Study Completion Date

April 4, 2012

Conditions

Bone Metastases

Interventions

BIOLOGICAL

Denosumab

Q4W 120 mg denosumab SC injection and 4 mg zoledronic acid (Zometa) placebo IV over a minimum of 15 minutes

DRUG

Zoledronic Acid

Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

Daiichi Sankyo

INDUSTRY

lead

Amgen

INDUSTRY